Literature DB >> 24682389

Cryptotanshinone inhibits lung tumorigenesis and induces apoptosis in cancer cells in vitro and in vivo.

Liang Chen1, Hui-Juan Wang2, Wenli Xie3, Yunyi Yao4, Yan-Shan Zhang5, Huiling Wang1.   

Abstract

Cryptotanshinone is one of the compounds extracted from the root of Salvia miltiorrhiza Bunge. Unlike other tanshinones, only a small number of studies have focused on cryptotanshinone for medical treatment. In the present study, the A549 lung cancer cell line and xenograft models of human lung tumors were used to assess the anti-cancer effect of cryptotanshinone. The effect of cryptotanshinone on human lung cancer, including growth inhibition, cell cycle arrest and apoptosis factors, were identified in vitro, and inhibition of tumor formation, improvement of body condition as well as pathological apoptotic effects were detected in vivo. These results suggested that cryptotanshinone is a potential drug for the treatment and prevention of human lung cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24682389     DOI: 10.3892/mmr.2014.2093

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  13 in total

1.  Cryptotanshinone, a Stat3 inhibitor, suppresses colorectal cancer proliferation and growth in vitro.

Authors:  Weidong Li; Shakir M Saud; Matthew R Young; Nancy H Colburn; Baojin Hua
Journal:  Mol Cell Biochem       Date:  2015-04-26       Impact factor: 3.396

2.  Isocryptotanshinone Induced Apoptosis and Activated MAPK Signaling in Human Breast Cancer MCF-7 Cells.

Authors:  Xuenong Zhang; Weiwei Luo; Wenwen Zhao; Jinjian Lu; Xiuping Chen
Journal:  J Breast Cancer       Date:  2015-06-26       Impact factor: 3.588

3.  Cryptotanshinone inhibits human glioma cell proliferation in vitro and in vivo through SHP-2-dependent inhibition of STAT3 activation.

Authors:  Liang Lu; Sulin Zhang; Cuixian Li; Chun Zhou; Dong Li; Peiqing Liu; Min Huang; Xiaoyan Shen
Journal:  Cell Death Dis       Date:  2017-05-11       Impact factor: 8.469

4.  Cryptotanshinone potentiates the antitumor effects of doxorubicin on gastric cancer cells via inhibition of STAT3 activity.

Authors:  Jiye Wang; Guangji Zhang; Chunyan Dai; Xiufei Gao; Jianbin Wu; Li Shen; Zhe Chen; Pei Liu
Journal:  J Int Med Res       Date:  2017-01-25       Impact factor: 1.671

5.  Cryptotanshinone inhibits proliferation yet induces apoptosis by suppressing STAT3 signals in renal cell carcinoma.

Authors:  Zhiguo Chen; Rujian Zhu; Jiayi Zheng; Chen Chen; Chi Huang; Junjie Ma; Chen Xu; Wei Zhai; Junhua Zheng
Journal:  Oncotarget       Date:  2017-07-25

6.  Inhibitory effects of isocryptotanshinone on gastric cancer.

Authors:  Zhang-Ming Chen; Lei Huang; Miao-Miao Li; Lei Meng; Song-Cheng Ying; A-Man Xu
Journal:  Sci Rep       Date:  2018-06-18       Impact factor: 4.379

7.  Functional oral nanoparticles for delivering silibinin and cryptotanshinone against breast cancer lung metastasis.

Authors:  Ying Liu; Xingmei Xie; Xuefeng Hou; Junyi Shen; Jiangpei Shi; Haizhen Chen; Yuanzhi He; Zhi Wang; Nianping Feng
Journal:  J Nanobiotechnology       Date:  2020-05-30       Impact factor: 10.435

8.  Cryptotanshinone inhibits esophageal squamous-cell carcinoma in vitro and in vivo through the suppression of STAT3 activation.

Authors:  Yubin Ji; Yichen Liu; Nina Xue; Tingting Du; Liyuan Wang; Rui Huang; Ling Li; Chunhong Yan; Xiaoguang Chen
Journal:  Onco Targets Ther       Date:  2019-01-29       Impact factor: 4.147

9.  Attenuation of doxorubicin-induced cardiotoxicity by cryptotanshinone detected through association analysis of transcriptomic profiling and KEGG pathway.

Authors:  Le Li; Bin Wu; Qiangqiang Zhao; Jian Li; Yunfeng Han; Xiaohang Fan; Junli Dong; Pengcheng Li
Journal:  Aging (Albany NY)       Date:  2020-05-26       Impact factor: 5.682

10.  Cryptotanshinone induces cell cycle arrest and apoptosis through the JAK2/STAT3 and PI3K/Akt/NFκB pathways in cholangiocarcinoma cells.

Authors:  Fayong Ke; Zheng Wang; Xiaoling Song; Qiang Ma; Yunping Hu; Lin Jiang; Yijian Zhang; Yingbin Liu; Yong Zhang; Wei Gong
Journal:  Drug Des Devel Ther       Date:  2017-06-15       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.